Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 259

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 259
---
 to be effective immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. Compensation Committee Upon completion of this offering, our compensation committee will consist of , , and , with serving as chair of the compensation committee. Our board of directors has determined that each of the members of our compensation committee is independent under the listing standards of Nasdaq and qualifies as a “non-employee director”as defined in Rule 16b-3 promulgatedunder the Exchange Act. The primary responsibilities of the compensation committee will include, among other things:

| • |     | reviewing and approving (or, as applicable, recommending to our board of directors) the compensation of our Chief 
 Executive Officer and other executive officers;                                                                   |

| • |     | reviewing and approving the compensation paid to our non-employee 
 directors;                                                        |

| • |     | administering our equity incentive plans and other benefit programs; |

| • |     | reviewing and approving, or making recommendations to our board of directors with respect to, incentive 
 compensation and equity plans;                                                                          |

| • |     | reviewing, adopting, amending, and terminating the terms of any employment agreements, severance arrangements,                               
 bonus plans, deferred compensation plans, change-of-control protections, and any other compensatory arrangements for our executive officers; |

| • |     | reviewing, evaluating, and recommending to our board of directors succession plans for our executive officers; 
 and                                                                                                            |

| • |     | reviewing and establishing general policies relating to compensation and benefits of our employees, including our 
 overall compensation philosophy.                                                                                  |

The compensation committee will operate under a written charter, to be effective immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. 178

Nominating and Corporate Governance Committee Upon completion of this offering, our nominating and corporate governance committee will consist of and , with serving as chair of the nominating and corporate governance committee. Our board of directors has determined that each of these individuals is “independent” as defined under the applicable listing standards of Nasdaq and SEC rules and regulations. The primary responsibilities of the nominating and corporate governance committee will include, among other things:

| • |     | identifying, reviewing, and evaluating candidates, including the nomination of incumbent directors for reelection 
 and nominees recommended by our stockholders, to serve on our board of directors;                                 |

| • |     | considering and making recommendations to